PTC Therapeutics | PTCT - Selling And Administration Expenses

Stock Price
69.51
Daily Change
-1.15 -1.63%
Monthly
-8.01%
Yearly
37.13%
Q1 Forecast
68.47

PTC Therapeutics reported $87.2M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amgen USD 1.94B 237M Dec/2025
BioCryst Pharmaceuticals USD 80.47M 15.39M Dec/2024
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Cytokinetics USD 158.75M 93.03M Sep/2025
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Esperion Therapeutics USD 39.98M 4.21M Sep/2024
Gilead Sciences USD 1.78B 425M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
Karyopharm Therapeutics USD 27.19M 442K Dec/2024
Novartis USD 3.31B 134M Sep/2025
Pfizer USD 4.08B 894M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Roche Holding CHF 7.28B 3.99B Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
TG Therapeutics USD 63.37M 51.33M Sep/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025
Xencor USD 87.78M 72.66M Sep/2025